eRAPID Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: randomised controlled trial in systemic cancer treatment

Conditions

Colorectal cancer, breast cancer, cervical cancer, ovarian cancer, rectal cancer or uterine cancer Cancer

Galina Velikova, Kate Absolom, Jenny Hewison, Patricia Holch, Lorraine Warrington et al. (23 authors)

Programme Grants for Applied Research2022-02-0120 citations

10.3310/fdde8516

Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy

Kate Absolom, Lorraine Warrington, Eleanor Hudson, Jenny Hewison, Carolyn Morris et al. (20 authors)

Journal of Clinical Oncology2021-01-08269 citations

10.1200/jco.20.02015

Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and advice)—An eHealth intervention during chemotherapy.

Galina Velikova, Kate Absolom, Lorraine Warrington, Carolyn Morris, Eleanor Hudson et al. (11 authors)

Journal of Clinical Oncology2020-05-2013 citations

10.1200/jco.2020.38.15_suppl.7002

Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment.

Holch P, Warrington L, Bamforth LCA, Keding A, Ziegler LE, Absolom K, Hector C, Harley C, Johnson O, Hall G, Morris C, Velikova G.

2017-09-0180 citations

10.1093/annonc/mdx317

Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID): a randomised controlled trial in systemic cancer treatment

Kate Absolom, Patricia Holch, Lorraine Warrington, Faye Samy, Claire Hulme et al. (12 authors)

BMC Cancer2017-05-0861 citations

10.1186/s12885-017-3303-8

Interventions

Participants allocated to the intervention arm will have access to the eRAPID online system for self-reporting symptoms and side effects/adverse events (AE) during systemic cancer treatment. eRAPID al

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult patients (aged 18 years or over) attending St James? University Hospital diagnosed with early breast or colorectal cancer requiring adjuvant systemic treatment, or gynaecological cancer requiring chemotherapy (recruitment may be extended in the main trial to include testicular cancer patients receiving systemic therapy) 2. Prescribed at least three months of planned chemotherapy cycles at the time of study consent 3. Able and willing to give informed consent 4. Able to read and understand English 5. Access to the internet at home

Exclusion criteria

Exclusion criteria: Patients who are: 1. Taking part in other clinical trials involving the completion of extensive patient reported outcome or quality of life measures 2. Exhibiting overt psychopathology/cognitive dysfunction

Design outcomes

Primary

Measure	Time frame
Clinical outcomes and process of care measures; Timepoint(s): Throughout 18 week study period	—

Secondary

Measure	Time frame
1. Costs to patients and the NHS; Timepoint(s): Throughout 18 week study period 2. Patient-reported outcomes; Timepoint(s): Baseline, 6, 12, 18 weeks	—

Countries

United Kingdom

Outcome results

None listed